Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
This trial investigates the effects of different durations of fasting after esophageal variceal ligation therapy in patients with cirrhosis and portal hypertension. Researchers aim to compare early postoperative oral intake with a 6-hour fasting period against delayed oral intake with fasting periods of 24 or 48 hours. The study evaluates the safety and effectiveness of these approaches in reducing early postoperative rebleeding. Participants are randomly assigned to one of three groups with varying fasting durations after ligation surgery 6 hours, 24 hours, or 48 hours. The 6-hour fasting group begins with a liquid diet during the first day after surgery, progressing to semi-liquid or soft diets by days 4-7, and regular diets starting day 8. The groups fasting 24 or 48 hours receive intravenous fluids during fasting, followed by gradual diet progression similar to the 6-hour group. This study is conducted across multiple centers and uses a quadruple-blind design. During the study, participants will be monitored for early rebleeding events over 6 weeks, with additional assessments of hospital stay length, nutritional status, and non-bleeding adverse events over 4 weeks. Researchers will track diet tolerance and complications through scheduled visits and evaluations. The study runs from June 2026 to June 2027, with careful safety and outcome monitoring to understand the impact of fasting duration on recovery after variceal ligation.
Actively Recruiting
Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.
Actively Recruiting
Researchers are evaluating whether stopping oral anticoagulant medication after a successful atrial fibrillation ablation can lower bleeding risks without increasing the chances of death or blood clots. This randomized, open-label trial involves adults aged 18 to 80 years who are between 60 and 365 days post-ablation, have a specific risk score of 2 or higher, no prior stroke or embolism, continuous use of certain anticoagulants, and no signs of recurring atrial arrhythmia. Participants are randomly assigned to either stop their anticoagulant medication immediately or continue taking it according to guidelines. All participants undergo close heart rhythm monitoring using a smartwatch capable of single-lead ECG and scheduled Holter or ECG patch monitoring at least every six months, with encouraged monitoring every two months. If any recurrence of atrial arrhythmia is detected, participants exit the trial. Study visits occur at months 3 and 6 after randomization, then every six months, with additional follow-ups every two months. Throughout the study, researchers collect data on serious outcomes including death, stroke, systemic embolism, and bleeding events for up to 48 months. They also assess quality of life, anxiety, depression, and atrial fibrillation recurrence through questionnaires. The study includes a planned 4,100 participants and is sponsored by Beijing Anzhen Hospital, aiming to provide detailed safety and effectiveness information on anticoagulation management after atrial fibrillation ablation.
Actively Recruiting
Randomized, Double-Blind Study of Yufeng Ningxin Tablets Versus Placebo for Adults With Hypertension
Researchers are evaluating the effects of Yufeng Ningxin, a traditional Chinese medicine, on patients with hypertension. Although previous animal studies and small clinical trials have suggested that Yufeng Ningxin may lower blood pressure, this phase 4 double-blind, randomized controlled trial aims to rigorously assess its efficacy and safety in a larger patient group. The trial is sponsored by Beijing Anzhen Hospital and focuses on adults aged 18 to 65 with newly diagnosed or treated hypertension. Participants are randomly assigned to one of two groups one group receives Yufeng Ningxin tablets, and the other receives a matching placebo. Both treatments are taken as five tablets per dose, three times daily for eight weeks. The study uses a quadruple masking design to ensure unbiased results. The primary treatment period lasts eight weeks, during which participants take the study medication as directed. During the trial, participants will undergo regular blood pressure measurements and assessments of other health markers related to hypertension, including ambulatory blood pressure monitoring and blood tests for cholesterol and glucose levels. Researchers will also analyze changes in gut microbiota and headache impact scores. Safety is monitored through tracking adverse events, hospitalizations, and emergency visits throughout the eight weeks. Participants will be closely followed to measure the change in systolic blood pressure from the start to the end of treatment.
Actively Recruiting
Researchers are conducting a multicenter, prospective observational study across 200 hospitals in China to examine current treatment patterns for chronic hepatitis B CHB. The study aims to compare patient outcomes under different treatment regimens to provide evidence-based data that can improve CHB treatment strategies and follow-up care, ultimately advancing efforts toward a functional cure for chronic hepatitis B. Participants include those receiving or planned to receive treatments such as entecavir ETV, tenofovir disoproxil fumarate TDF, tenofovir alafenamide fumarate TAF, tenofovir amibufenamide TMF, or peginterferon alpha-2b injection. The study observes real-world clinical practice without assigning treatments, capturing data on these therapies over an extended period. During the study, researchers will monitor outcomes including the percentage of patients developing HBsAg-associated hepatocellular carcinoma HCC, incidence of HCC, rates of HBsAg seroclearance and seroconversion, changes in HBsAg levels, HBV DNA levels, liver fibrosis improvement, and liver-related complications. Data collection spans from week 4 up to week 240, with continuous follow-up to assess treatment effects and patient status over time.
Actively Recruiting
Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.